PMID- 37244382
OWN - NLM
STAT- MEDLINE
DCOM- 20230615
LR  - 20230916
IS  - 1874-1754 (Electronic)
IS  - 0167-5273 (Linking)
VI  - 386
DP  - 2023 Sep 1
TI  - Comparison of oral anticoagulation by vitamin-K antagonists and non-vitamin-K 
      antagonists for treatment of leaflet thickening after transcatheter aortic valve 
      implantation (TAVI).
PG  - 104-108
LID - S0167-5273(23)00727-1 [pii]
LID - 10.1016/j.ijcard.2023.05.034 [doi]
AB  - INTRODUCTION: Hypoattenuated leaflet thickening (HALT), as identified by CT 
      imaging, is not infrequent after transcatheter aortic valve implantation (TAVI). 
      The best choice of oral anticoagulation is unknown. We compared the effectiveness 
      of Direct Oral AntiCoagulants (DOAC) and Vitamin-K Antagonists (VKA) to resolve 
      HALT in patients with serial CT aquisitions. METHODS: A total of 46 consecutive 
      TAVI patients in whom anticoagulation had been initiated because of HALT and who 
      underwent follow-up CT were identified. Indication and type of anticoagulation 
      was according to physician discretion. Patients on DOAC were compared to VKA 
      therapy regarding resolution of HALT. RESULTS: Mean age of the 46 patients was 
      80 +/- 6 years (59% men), and the mean duration of anticoagulation was 156 days. 
      Overall, 41 patients (89%) showed resolution of HALT with anticoagulation 
      therapy, whereas HALT persisted in 5 patients (11%). Resolution of HALT was seen 
      in 26 out of 30 (87%) patients receiving VKA and in 15 out of 16 (94%) patients 
      receiving DOAC, respectively. Groups did not differ regarding age, cardiovascular 
      risk factors, TAVI prosthesis type and size or duration of anticoagulation (all 
      p > 0.05). CONCLUSION: Anticoagulation therapy resolves leaflet thickening after 
      TAVI in most patients. Non-Vitamin-K antagonists seem to be an effective 
      alternative to Vitamin-K antagonists. This finding needs to be confirmed in 
      larger prospective trials.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Ferstl, P
AU  - Ferstl P
AD  - Friedrich-Alexander-Universitat (FAU) Erlangen-Nurnberg, Department of 
      Cardiology, Erlangen, Germany. Electronic address: paul.ferstl@uk-erlangen.de.
FAU - Achenbach, S
AU  - Achenbach S
AD  - Friedrich-Alexander-Universitat (FAU) Erlangen-Nurnberg, Department of 
      Cardiology, Erlangen, Germany.
FAU - Marwan, M
AU  - Marwan M
AD  - Friedrich-Alexander-Universitat (FAU) Erlangen-Nurnberg, Department of 
      Cardiology, Erlangen, Germany.
FAU - Bittner, D O
AU  - Bittner DO
AD  - Friedrich-Alexander-Universitat (FAU) Erlangen-Nurnberg, Department of 
      Cardiology, Erlangen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20230525
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Anticoagulants)
SB  - IM
CIN - Int J Cardiol. 2023 Oct 1;388:131140. PMID: 37356733
MH  - Male
MH  - Humans
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - *Transcatheter Aortic Valve Replacement/adverse effects
MH  - Aortic Valve/diagnostic imaging/surgery
MH  - *Aortic Valve Stenosis/diagnostic imaging/drug therapy/surgery
MH  - Prospective Studies
MH  - *Heart Valve Prosthesis
MH  - Anticoagulants
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Anticoagulation
OT  - HALT
OT  - Leaflet thickening
OT  - TAVI
EDAT- 2023/05/28 01:07
MHDA- 2023/06/15 06:42
CRDT- 2023/05/27 19:23
PHST- 2023/02/05 00:00 [received]
PHST- 2023/05/12 00:00 [revised]
PHST- 2023/05/17 00:00 [accepted]
PHST- 2023/06/15 06:42 [medline]
PHST- 2023/05/28 01:07 [pubmed]
PHST- 2023/05/27 19:23 [entrez]
AID - S0167-5273(23)00727-1 [pii]
AID - 10.1016/j.ijcard.2023.05.034 [doi]
PST - ppublish
SO  - Int J Cardiol. 2023 Sep 1;386:104-108. doi: 10.1016/j.ijcard.2023.05.034. Epub 
      2023 May 25.